Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK of E7386 in Healthy Men
NCT05607537Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of e7386 in solid tumor (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Percent Absolute Oral Bioavailability, Maximum Observed Plasma Concentration and 8 more. Started Oct 2022; status: completed.
02
Drugs
e7386
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05607537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607537.